Search results
Results From The WOW.Com Content Network
Invitae's estimated assets were in the $500 million - $1 billion range, while its liabilities were in the $1 billion - $10 billion range, according to the bankrup ... Clinical lab operator Labcorp ...
Invitae Corp. is a biotechnology company that was created as a subsidiary of Genomic Health in 2010 and then spun-off in 2012. [2] In 2017, Invitae acquired Good Start Genetics and CombiMatrix. [3] [4] In 2020, Invitae announced the acquisition of ArcherDX for $1.4 billion. [5]
Shares of the San Francisco-based company tumbled 69% to hit a record low of 11 cents after the report. An Invitae spokesperson told Reuters that the company did not comment on market rumors and ...
In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. [63] In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. [64] In July 2020, the company was processing 165,000 COVID-19 tests per day. [65]
In June 2021, the company changed its name to Labcorp Drug Development. [55] In February 2023, the company was renamed Fortrea Holdings. [56] In July 2023, Labcorp completed the corporate spin-off of the company. [57] In June 2024, the company sold its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners. [58]
For premium support please call: 800-290-4726 more ways to reach us
The Prospera test is the first assay with high sensitivity to both T-cell-mediated and antibody-mediated rejection. [ 13 ] [ 14 ] In December 2019, the test received final Medicare coverage. In 2020, Natera launched Renasight, a test to determine if there is a genetic cause for an individual's kidney disease and if there may be other at-risk ...
Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting ...